IMPACT ON DRUG DEVELOPMENT
The translational activities at the LSI of Dr. Cullis have resulted in the development of a series of new therapeutics. Dr. Cullis is an expert in the design of lipid nanoparticle (LNP) systems for the delivery of conventional small molecule drugs such as anticancer drugs as well as genetic drugs such as siRNA, antisense oligonucleotides and plasmids. In the case of small molecules LNP delivery leads to reduced toxicity and enhanced potency whereas LNP systems are required to enable the therapeutic potential of genetic drugs, which, in the free form, are readily broken down in the circulation, do not accumulate at sites of disease and cannot enter target cells.
Three drugs originating from the Cullis Lab have made it into the market:
|Drug||Trade Name||Indication||Status (2007)||Company|
|LNP Amphotericin||ABELCET||Fungal infections||Approved US,
|LNP Doxorubicin||Myocet||Metastatic Breast Cancer||Approved Europe,
|LNP Vincristine||Marqibo||Acute lymphocytic
A series of LNP based drugs for breast, lung and liver cancer and cystic fibrosis from the Cullis Lab are also at varying levels of clinical development that could be on the market in the next 5 years.